Compare Royal Caribbean Cruises Ltd (RCL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs ResMed Inc. — how do they compare? Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.4× ResMed Inc.'s market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and ResMed Inc. for 51 Days on average.
| RCL | RMD | |
|---|---|---|
Market Cap | $75.26B | $31.89B |
Volume | 1,958,628 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $277.88 |
52-Week Low | $230.30 | $182.82 |
Typical Hold Time | 85 Days | 51 Days |
Enterprise Value | $97.91B | $31.24B |
Dividend Yield | 2.13% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, showing modest daily weakness but maintaining strong bullish momentum with analyst consensus pointing to significant upside. The company demonstrates robust fundamentals with revenue growth from $8.8B in 2022 to $17.9B in 2025, net income margin expanding to 23.54%, and positive cash flow generation. Recent developments include a $3B investment in Sandals Resorts and strong Q2 2026 earnings beat, while technical indicators show the stock trading near key resistance levels with overall bullish signals.
RCL presents compelling investment potential with 23% upside to consensus price target of $346.67, supported by strong earnings momentum and expanding profitability. However, risks include elevated debt levels, execution challenges from the Sandals acquisition, and sensitivity to fuel price volatility. The stock's current valuation at 17.38x P/E appears reasonable given the company's growth trajectory and industry-leading margins.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
